



ENVIRONMENTAL PROTECTION AGENCY
WASHINGTON, D.C. 20460

OFFICE OF CHEMICAL SAFETY
AND POLLUTION PREVENTION

OFFICE OF PESTICIDE PROGRAMS
REGISTRATION DIVISION (7505P)

DOCUMENT CONTAINS CONFIDENTIAL INFORMATION

DATE OUT: January 23, 2017

DP BARCODE No.: 437134

REG. No.: 5905-579

Action Code: 345

Decision No: 524223

Company Name: Helena Chemical Company

SUBJECT: Product Chemistry Review of the EP. VELOSSA

PC Code: 107201

FROM: William Herald, Microbiologist (MS) /Chemist, NEHA/ REHS/ Registered Sanitarian
Product Chemistry Team
Chemistry, Inerts and Toxicology Assessment Branch (CITAB) RD (7505P)

TO: BeWanda Alexander / Eric Kraft, PM-24
Fungicide and Herbicide Branch/ RD (7505P)

Handwritten signature and date:
SF 01-23-17

INTRODUCTION:

With a letter dated November 3, 2016 and a subsequent e-mail communication dated January 23, 2017 Registrant, Helena Chemical Company has petitioned the Agency for approval of proposed Alt. Nos. B and C CSF formulations (both dated 1/23/17) to support the registration of the end use product, "VELOSSA". The proposed alternate CSF formulations slightly altered the amounts of some of the inert ingredients. CITAB has been asked to evaluate the said proposed alternate CSF formulations and determine their acceptability.

SUMMARY OF FINDINGS:

1. The end use product "VELOSSA" contains Hexazinone [REDACTED] Alt. No. B; or [REDACTED] Alt. No. C] as the active ingredient with the product label claim of 25%..
2. The said proposed Alt. No. B and C CSF formulations are filled out correctly and completely and is in compliance with PR Notice 91-2, and Title 40 CFR § 152.43. The upper and lower limits of the active and inert ingredients are in compliance with statutory parameters recited in Title 40 CFR § 158.350 (b) (2).
3. The nominal concentration of the active ingredient concurs with the product label claim of nominal concentration.
4. All of the inert ingredients present in the formulation have been approved by the Agency for food use under 920 (L. Austr, 12/9/16).
5. The said proposed Alt. Nos. B and C CSF formulations (both dated 1/23/17) are substantially similar in chemical composition and physical-chemical properties with the current Basic CSF (dated 5/19/2008)

CONCLUSION:

The CITAB has reviewed the propose Alt. Nos. B and C CSF formulations, both dated January 23, 2017 and has determined them to be acceptable.